Journal Mobile Options
Table of Contents
Vol. 36, No. 4, 2012
Issue release date: October 2012
Section title: Original Report: Patient-Oriented, Translational Research
Am J Nephrol 2012;36:362–370
(DOI:10.1159/000343281)

Prevalence of Cardiovascular Events in Patients with Autosomal Dominant Polycystic Kidney Disease

Helal I. · Reed B. · Mettler P. · Mc Fann K. · Tkachenko O. · Yan X.-D. · Schrier R.W.
Division of Renal Diseases and Hypertension, University of Colorado Denver, Aurora, Colo., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Report: Patient-Oriented, Translational Research

Received: 7/11/2012
Accepted: 9/10/2012
Published online: 10/4/2012

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 7

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: http://www.karger.com/AJN

Abstract

Background: This study evaluates the prevalence of cardiovascular events in autosomal dominant polycystic kidney disease (ADPKD) patients. Methods: We distributed surveys to 1,439 subjects from our ADPKD research database. In total, 426 subjects completed and returned surveys; 7 of these were from children and were excluded from the study. Results: The patients who responded were female (63.2%), nonHispanic (88.1%) and white (93.6%). The mean age of the total group was 53.2 ± 13.7 years; 82.8% had a family history of ADPKD and 32.5% had reached end-stage renal disease (ESRD). With respect to cardiovascular risk factors, 86.6% were hypertensive with a mean age at diagnosis of 36.9 ± 12.9 years and hypertension was significantly more prevalent in males. In addition, 19.6% of the subjects were obese, 20.8% were smokers, 8.7% had diabetes, 45.7% had high cholesterol and 17.8% were sedentary. The most prevalent self-reported cardiovascular events were arrhythmias (25.9%), evidence of peripheral vascular disease (16.5%), heart valve problems (14.4%), cardiac enlargement (9.5%), stroke or cerebral bleeding (7.5%), myocardial infarction (6%) and brain aneurysm (5.0%). The most commonly used antihypertensive medications were renin-angiotensin inhibitors used by 75% of ADPKD patients. Older ADPKD patients and those at ESRD had a significantly higher incidence of cardiovascular events. Conclusion: These findings support the high prevalence of cardiovascular risk factors and events in ADPKD patients which contribute to a greater mortality risk. Due to the prevalence of cardiovascular risk factors in the ADPKD population, early diagnosis and clinical intervention are recommended.


Article / Publication Details

First-Page Preview
Abstract of Original Report: Patient-Oriented, Translational Research

Received: 7/11/2012
Accepted: 9/10/2012
Published online: 10/4/2012

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 7

ISSN: 0250-8095 (Print)
eISSN: 1421-9670 (Online)

For additional information: http://www.karger.com/AJN


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. McCullough PA: Scope of cardiovascular complications in patients with kidney disease. Ethn Dis 2002;12:44–48.
  2. U.S. Renal Data System: USRDS 2011 Annual Data Report, 2011.
  3. Schrier RW: Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology 2006;11:124–130.
  4. Ecder T, Schrier RW: Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 2009;5:221–228.
  5. Florijin KW, Noteboom WM, Van Saase JL, Chang PC, Breuning MH, Vandenbroucke JP: A century of mortality in five large families with polycystic kidney disease. Am J Kidney Dis 1995;25:370–374.

    External Resources

  6. Fick GM, Johnson AM, Hammond WS, Gabow PA: Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5:2048–2056.
  7. Schrier RW, McFann KK, Johnson AM: Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 2003;63:678–685.
  8. Patch C, Charlton J, Roderick PJ, Gulliford MC: Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 2011;57:856–862.
  9. Orskov B, Rømming Sørensen V, Feldt-Rasmussen B, Strandgaard S: Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol 2010;5:2034–2039.
  10. Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW: Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001;21:98–103.
  11. Iglesias C, Torres V, Offord K, Holley K, Beard C, Kurland L: Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935–1980. Am J Kidney Dis 1983;2:630 -639.
  12. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992;41:1311–1319.
  13. Zeier M, Geberth S, Schmidt KG, Mandelbaum A, Ritz E: Elevated blood pressure profile and left ventricular mass in children and young adults with adult polycystic kidney disease. J Am Soc Nephrol 1993;3:1451–1457.
  14. Chapman AB, Schrier RW: Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin Nephrol 1991;11:653–660.
  15. Ecder T, Schrier RW: Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001;12:194–200.
  16. Schrier RW, Johnson AM, McFann K, Chapman AB: The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 2003;64:1792–1799.
  17. Milutinovic J, Fialkow PJ, Agodoa LY, Phillips PA, Rudd TG, Bryant JI: Adult polycystic kidney disease symptoms and clinical findings. Q J Med 1984;53:511–522.
  18. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW: The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010;5:102–109.
  19. Chaveau D, Pirson Y, Verellen-Dumoulin C, Macnicol A, Gonzalo A, Grunfeld JP: Intracranial aneurysms in autosomal dominant polycystic kidney disease. Kidney Int 1994;45:1140–1146.

    External Resources

  20. Pietrzak-Nowacka M, Safranow K, Byra E, Bińczak-Kuleta A, Ciechanowicz A, Ciechanowski K: Metabolic syndrome components in patients with autosomal-dominant polycystic kidney disease. Kidney Blood Press Res 2009;32:405–410.
  21. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relationship of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345–352.
  22. Chapman AA: Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997;8:1292–1297.
  23. Saggar-Malik A, Missouris CG, Gill JS, Singer DR, Markandu ND, MacGregor GA: Left ventricular mass In normotensive subjects with autosomal dominant polycystic kidney disease. BMJ 1994;309:1617–1618.
  24. Bardaji A, Vea AM, Gutierrez C, Ridao C, Richart C, Oliver JA: Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998;32:970–975.
  25. Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Bae KT, HALT PKD Study Group, Meyers CM: Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:2508–2515.

    External Resources

  26. Ivy DD, Shaffer EM, Johnson AM, Kimberling WJ, Dobin A, Gabow PA: Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5:2032–2036.
  27. Bardaji A, Martinez-Vea A, Valero A, Gutierrez C, Garcia C, Ridao C, Oliver JA, Richart C: Cardiac involvement in autosomal dominant polycystic kidney disease: a hypertensive heart disease. Clin Nephrol 2002;56:211–220.

    External Resources

  28. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW: Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 2008;74:1192–1196.

    External Resources

  29. Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, Brosnahan GM, Schrier RW: Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1999;14:1113–1116.
  30. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002;13:1733–1739.
  31. Hossack KF, Leddy CL, Johnson AM, Schrier RW, Gabow PA: Echocardiographic findings in autosomal dominant polycystic kidney disease. N Engl J Med 1988;319:907–912.
  32. Pirson Y, Christophe JL, Goffin E: Outcome of renal replacement therapy in adult polycystic kidney disease. Nephrol Dial Transplant 1996;11:24–28.

    External Resources

  33. Ritz E, Zeier M, Schneider P, Jones E: Cardiovascular mortality of patients with polycystic kidney disease on dialysis: is there a lesson to learn? Nephron 1994;66:125–128.
  34. Verdalles U, Abad S, Vega A, Ruiz Caro C, Ampuero J, Jofre R, Lopez-Gomez JM: Factors related to the absence of anemia in hemodialysis patients. Blood Purif 2011;32:69–74.
  35. Chapman AB, Rubinstein D, Hughes R, Stears JC, Earnest MP, Johnson AM, Gabow PA, Kaehny WD: Intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 1992;327:916–920.
  36. Ruggleri PM, Poulos N, Masaryk TJ, Ross JS, Obuchowski NA, Awad IA, Braun WE, Nally J, Lewin JS, Modic MT: Occult intracranial aneurysms in polycystic kidney disease: screening with MR angiography. Radiology 1994;191:33–39.
  37. Hadimeri H, Lamm C, Nyberg G: Coronary aneurysms in patients with adult polycystic kidney disease. J Am Soc Nephrol 1998;9:837–841.
  38. Montoliu J, Torras A, Revert L: Polycystic kidneys and abdominal aortic aneurysms. Lancet 1980;1:1133–1134.
  39. Chapman AB & Hilson AJW: Polycystic kidneys and abdominal aortic aneurysms. Lancet 1980;1:646–647.
  40. Torra R, Nicolau C, Badenas C, Brú C, Pérez L, Estivill X, Darnell A: Abdominal aortic aneurysms and adult polycystic kidney disease. J Am Soc Nephrol 1996;7:2483–2486.
  41. Huston J, Torres VE, Sullivan PP, Offord KP, Wiebers DO: Value of magnetic resonance angiography for the detection of intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993;3:1871–1877.
  42. Konoshita T, Okamoto K, Koni I, Mabuchi H: Clinical characteristics of polycystic kidney disease with end-stage renal disease. Clin Nephrol 1998;50:113–118.
  43. Christophe JL, Van Ypersele de Strihou C, Pirson Y: Complications of autosomal dominant polycystic kidney disease in 50 haemodialysed patients. A case-control study. Nephrol Dial Transplant 1996;11:1271–1276.
  44. Zeier M, Geberth S, Ritz E, Jaeger T, Waldherr R: Autosomal dominant polycystic kidney disease – clinical problems. Nephron 1988;49:177–183.
  45. Schievink WI, Torres VE, Piepgras DG, Wiebers DO: Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1992;3:88–95.
  46. Wiebers DO, Torres VE: Screening for unruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. N Engl J Med 1992;327:953–955.
  47. Xu HW, Yu SQ, Mei CL, Li MH: Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease. Stroke 2011;42:204–206.
  48. Irazabal MV, Huston J 3rd, Kubly V, Rossetti S, Sundsbak JL, Hogan MC, Harris PC, Brown RD Jr, Torres VE: Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:1274–1285.

    External Resources

  49. Sarnak MJ: Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003;41:11–17.